Page last updated: 2024-08-23

razoxane and Heart Diseases

razoxane has been researched along with Heart Diseases in 72 studies

Research

Studies (72)

TimeframeStudies, this research(%)All Research%
pre-19906 (8.33)18.7374
1990's33 (45.83)18.2507
2000's21 (29.17)29.6817
2010's12 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adamcová, M; Geršl, V; Hroch, M; Jirkovský, E; Lenčová-Popelová, O; Mazurová, Y; Mičuda, S; Šimůnek, T; Štěrba, M; Vávrová, J1
Jones, RL1
Belhani, D; Bui-Xuan, B; Descotes, J; Fanton, L; Manati, W; Tabib, A; Timour, Q; Vaillant, F1
Adamcová, M; Gersl, V; Guncová, I; Hasková, P; Hroch, M; Mazurová, Y; Nachtigal, P; Popelová, O; Simůnek, T; Sterba, M1
Herman, EH; Honchel, R; Knapton, AD; Lipshultz, SE; Retief, J; Rosenzweig, BA; Sistare, FD; Thompson, KL; Zhang, J1
Gallegos-Castorena, S; Gonzalez-Ramella, O; Sánchez-Medina, J1
Beijnen, JH; Goey, AK; Huitema, AD; Schellens, JH1
Anderson, P; Chandra, J; Fulbright, JM; Huh, W1
Dervisis, NG; FitzPatrick, WM; Kitchell, BE1
McBride, D1
Caron, HN; Dickinson, HO; Kremer, LC; van Dalen, EC1
Agee, S; Estis, J; Hasinoff, B; Herman, EH; Knapton, A; Lipshultz, S; Lu, QA; Rosen, E; Rosenzweig, B; Thompson, K; Todd, JA; Zhang, J1
Che, F; Liu, Y; Xu, C1
Doroshow, JH1
Franco, VI; Harake, D; Henkel, JM; Lipshultz, SE; Miller, TL1
Ostański, M; Sońta-Jakimczyk, D1
Alpert, L; Bernier, M; Chalifour, LE; Dostanic, S; Héon, S; Kirby, GM; Servant, N; Wang, C1
Komagata, H; Sakai, H1
Chitambar, CR; Joseph, J; Kalivendi, SV; Kalyanaraman, B; Konorev, E; Kotamraju, S1
Gershanovich, ML2
Arsovski, O; Debourdeau, P; Gligorov, J; Lotz, JP1
Campos, O; Macedo, CR; Moisés, VA; Paiva, MG; Petrilli, AS; Tanaka, C1
Charlier, H; Cusack, BJ; Gambliel, H; Hadjokas, N; Musser, B; Olson, RD; Shadle, SE1
Chauvenet, A; Constine, LS; De Alarcon, PA; Friedman, D; London, WB; Mendenhall, NP; Schwartz, CL; Sposto, R; Tebbi, CK; Villaluna, D1
Caron, HN; Kremer, LC; van Dalen, EC1
Alvarez, JA; Barry, E; Lipshultz, SE; Miller, TL; Scully, RE1
Hasinoff, BB; Herman, EH1
Jensen, PB; Langer, SW; Sehested, M1
Azarova, AM; Ban, Y; Kerrigan, JE; Lin, CP; Liu, LF; Lyu, YL; Tsai, YC1
Hochster, H; Speyer, J; Wasserheit, C1
Armand, JP; de Forni, M1
Bastholt, L; Gjedde, SB; Jakobsen, P; Mirza, MR; Mouridsen, HT; Rose, C; Sørensen, B1
Bu'Lock, FA; Gabriel, HM; Martin, RP; Mott, MG; Oakhill, A1
Catimel, G; Clavel, M; Merrouche, Y1
Alberts, DS; Dawson, BV; Dorr, RT; Hendrix, M; Shipp, NG1
Ferrans, VJ; Herman, EH; Zhang, J1
Lipshultz, SE1
Hellmann, K3
Besse, P; Bonoron-Adèle, S; Gouverneur, G; Pouna, P; Robert, J; Tariosse, L1
Bellina, RC; Bruzzi, P; Carnino, F; Conte, PF; Cyrus, P; Del Mastro, L; Gallo, L; Garrone, O; Guelfi, M; Lionetto, R; Michelotti, A; Molea, N; Pronzato, P; Rosso, R; Testore, F; Tibaldi, C; Venturini, M; Vinke, J1
Betcher, DL; O'Marcaigh, AS1
Grossmann, V; Kvĕtina, J; Safárová, M; Svoboda, Z1
Blum, RH1
Semiglazov, VF1
Phillips, KA; Tannock, IF1
Swain, SM1
Lopez, M; Vici, P1
Lemez, P; Maresová, J1
Wexler, LH1
Doroshow, JH; Synold, TW; Tetef, ML1
Spencer, CM; Wiseman, LR1
Mazzarello, GP; Morra, L1
Chadwick, DP; Ferrans, VJ; Herman, EH; Zhang, J1
Chakrabarti, KB; Hopewell, JW; Plowman, PN; Wilding, D1
Green, MR; Herndon, JE; Kindler, HL; Kosty, MP; Vogelzang, NJ1
Arundell, E; Bates, M; Lieu, D; Tonkin, K; Williamson, T; Zagari, M1
Ardalan, B; Bier, C; Herman, E; Krop, S; Waravdekar, V1
Blum, RH; Green, M; Hochster, H; Liebes, L; Meyers, M; Oratz, R; Speyer, JL; Wadler, S; Wernz, JC1
Carlson, RW1
Creighton, AM; Hopewell, JW; Jaenke, RS; Wilding, D; Yeung, TK1
Forbes, JF1
Curran, CF; Narang, PK; Reynolds, RD1
Baba, H; Bull, JM; Newman, RA; Ohno, S; Siddik, ZH; Stephens, LC; Strebel, FR1
Cova, D; Favalli, L; Galimberti, M; Lanza, E; Monti, E; Poggi, P; Rozza-Dionigi, A; Villani, F1
el-Hage, A; Ferrans, VJ; Herman, EH1
Ferrans, VJ; Herman, EH1
Ferrans, VJ; Hamlin, RL; Herman, EH; Young, RS1
Bhat, HB; Ferrans, VJ; Herman, EH; Witiak, DT1

Reviews

28 review(s) available for razoxane and Heart Diseases

ArticleYear
Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:10

    Topics: Aged; Animals; Anthracyclines; Antibiotics, Antineoplastic; Bone Marrow; Cardiotonic Agents; Chelating Agents; Child; Clinical Trials as Topic; Drug Evaluation, Preclinical; Heart Diseases; Humans; Neoplasms; Razoxane

2008
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154

    Topics: Anthracyclines; Cardiovascular Agents; Heart Diseases; Heart Failure; Humans; Randomized Controlled Trials as Topic; Razoxane

2010
Can anthracycline therapy for pediatric malignancies be less cardiotoxic?
    Current oncology reports, 2010, Volume: 12, Issue:6

    Topics: Adolescent; Adult; Anthracyclines; Child; Delayed-Action Preparations; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Carriers; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Heart; Heart Diseases; Heart Failure; Humans; Iron Chelating Agents; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Risk Factors; Treatment Outcome

2010
Cardioprotective interventions for cancer patients receiving anthracyclines.
    The Cochrane database of systematic reviews, 2011, Jun-15, Issue:6

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Cytoprotection; Heart Diseases; Humans; Neoplasms; Randomized Controlled Trials as Topic; Razoxane

2011
Dexrazoxane for the prevention of cardiac toxicity and treatment of extravasation injury from the anthracycline antibiotics.
    Current pharmaceutical biotechnology, 2012, Volume: 13, Issue:10

    Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiotonic Agents; Extravasation of Diagnostic and Therapeutic Materials; Heart Diseases; Humans; Injections, Intravenous; Iron; Razoxane; Reactive Oxygen Species

2012
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
    Future cardiology, 2012, Volume: 8, Issue:4

    Topics: Adiponectin; Age Factors; Angiotensin-Converting Enzyme Inhibitors; Anthracyclines; Antibiotics, Antineoplastic; Antioxidants; Carbazoles; Cardiolipins; Cardiotonic Agents; Carvedilol; Doxorubicin; Erythropoietin; Heart; Heart Diseases; Humans; Lipid Peroxidation; Liposomes; Neoplasms; Piperazines; Propanolamines; Purines; Razoxane; Risk Factors; Sildenafil Citrate; Sulfones; Survivors; Ventricular Dysfunction, Left

2012
[Chemotherapy-induced cardiac toxicity and management].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:6

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Echocardiography; Heart; Heart Diseases; Humans; Monitoring, Physiologic; Neoplasms; Razoxane

2003
Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis.
    Methods in enzymology, 2004, Volume: 378

    Topics: Aconitate Hydratase; Animals; Antibiotics, Antineoplastic; Antioxidants; Apoptosis; Caspases; Cells, Cultured; Chelating Agents; Cytochromes c; Doxorubicin; Endothelium; Heart Diseases; Humans; Iron; Iron Chelating Agents; Iron Regulatory Protein 1; Iron-Regulatory Proteins; Mitochondria; Muscle Cells; Oxidants; Oxidation-Reduction; Oxidative Stress; Razoxane; Reactive Oxygen Species; Receptors, Transferrin; Response Elements; RNA, Messenger; Signal Transduction; Superoxides; Up-Regulation

2004
[Cardiac prevention: the oncologic point of view].
    Bulletin du cancer, 2004, Volume: 91 Suppl 3

    Topics: Age Factors; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Heart; Heart Diseases; Humans; Liposomes; Paclitaxel; Razoxane; Risk Factors; Trastuzumab

2004
Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:7

    Topics: Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Child; Coenzymes; Heart Diseases; Humans; Randomized Controlled Trials as Topic; Razoxane; Risk Factors; Ubiquinone

2007
Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:8

    Topics: Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Drug Interactions; Drug Monitoring; Heart; Heart Diseases; Humans; Neoplasms; Razoxane; Risk Factors

2007
Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
    Cardiovascular toxicology, 2007, Volume: 7, Issue:2

    Topics: Animals; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Enzyme Inhibitors; Heart Diseases; Humans; Neoplasms; Prodrugs; Razoxane; Topoisomerase II Inhibitors

2007
Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Cardiovascular toxicology, 2007, Volume: 7, Issue:2

    Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Cardiovascular Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heart Diseases; Humans; Mice; Razoxane

2007
Cardiotoxicity and cardioprotection during chemotherapy.
    Current opinion in oncology, 1995, Volume: 7, Issue:4

    Topics: Adult; Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Cyclophosphamide; Female; Fluorouracil; Heart; Heart Diseases; Humans; Interleukin-2; Male; Neoplasms; Paclitaxel; Razoxane; Retrospective Studies; Survivors

1995
Cardiotoxicity of chemotherapy.
    Current opinion in oncology, 1994, Volume: 6, Issue:4

    Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Fluorouracil; Heart Diseases; Humans; Mice; Mitoxantrone; Neoplasms; Paclitaxel; Prospective Studies; Rabbits; Rats; Razoxane

1994
Hematopoietic growth factors and chemoprotectants: should we move toward a two-step process for phase I clinical trials in oncology?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:6

    Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Kidney Diseases; Neoplasms; Neutropenia; Razoxane

1993
Dexrazoxane (ICRF-187): a cardioprotective agent during anthracycline chemotherapy.
    Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses, 1997, Volume: 14, Issue:2

    Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Diseases; Humans; Razoxane

1997
Clinical status and optimal use of the cardioprotectant, dexrazoxane.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:11

    Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Cardiovascular Agents; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart; Heart Diseases; Humans; Iron; Myocardium; Razoxane; Safety; Treatment Outcome

1997
[Preventing the cardiotoxic effects of anthracyclines with Cardioxane].
    Voprosy onkologii, 1997, Volume: 43, Issue:6

    Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane

1997
Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Amifostine; Antineoplastic Agents; Cardiovascular Agents; Clinical Trials, Phase III as Topic; Heart Diseases; Hematopoietic Cell Growth Factors; Humans; Leukopoiesis; Randomized Controlled Trials as Topic; Razoxane; Research Design; Thrombocytopenia

1998
Overview and historical development of dexrazoxane.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Adult; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane

1998
Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Dose-Response Relationship, Drug; Doxorubicin; Female; Heart Diseases; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Randomized Controlled Trials as Topic; Razoxane

1998
European trials with dexrazoxane in amelioration of doxorubicin and epirubicin-induced cardiotoxicity.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Heart Diseases; Humans; Razoxane

1998
Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Anthracyclines; Antineoplastic Agents; Cardiovascular Agents; Child; Clinical Trials as Topic; Heart Diseases; Humans; Razoxane

1998
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
    Drugs, 1998, Volume: 56, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Chelating Agents; Heart Diseases; Humans; Neoplasms; Razoxane

1998
[Anthracyclines and the heart].
    Recenti progressi in medicina, 1998, Volume: 89, Issue:9

    Topics: Anthracyclines; Cardiovascular Agents; Heart; Heart Diseases; Humans; Razoxane

1998
Long-term effects of adjuvant chemotherapy in breast cancer.
    Acta oncologica (Stockholm, Sweden), 1992, Volume: 31, Issue:2

    Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Female; Heart; Heart Diseases; Hodgkin Disease; Humans; Leukemia; Lymphatic Metastasis; Menopause; Menstruation; Monitoring, Physiologic; Neoplasms, Second Primary; Ovary; Razoxane

1992
Toxicity profile of dexrazoxane (Zinecard, ICRF-187, ADR-529, NSC-169780), a modulator of doxorubicin cardiotoxicity.
    Cancer treatment reviews, 1991, Volume: 18, Issue:4

    Topics: Animals; Doxorubicin; Heart Diseases; Humans; Razoxane

1991

Trials

10 trial(s) available for razoxane and Heart Diseases

ArticleYear
Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography.
    Pediatric blood & cancer, 2005, Volume: 45, Issue:7

    Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Blood Pressure; Cardiotonic Agents; Child; Dobutamine; Doxorubicin; Drug Antagonism; Echocardiography, Stress; Female; Heart Diseases; Heart Rate; Humans; Male; Osteosarcoma; Razoxane; Ventricular Function, Left

2005
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Feb-10, Volume: 25, Issue:5

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chelating Agents; Cohort Studies; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid; Lung Diseases; Male; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Osteosarcoma; Razoxane; Risk Assessment; Risk Factors; Thyroid Neoplasms; Time Factors; Topoisomerase II Inhibitors

2007
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients.
    Cancer chemotherapy and pharmacology, 1994, Volume: 35, Issue:1

    Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chromatography, High Pressure Liquid; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Heart Diseases; Humans; Middle Aged; Neoplasm Metastasis; Razoxane; Tamoxifen

1994
Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
    British heart journal, 1993, Volume: 70, Issue:2

    Topics: Adolescent; Antibiotics, Antineoplastic; Child; Child, Preschool; Heart; Heart Diseases; Humans; Neoplasms; Pilot Projects; Razoxane

1993
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:12

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Epirubicin; Female; Heart Diseases; Humans; Middle Aged; Razoxane

1996
Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone- and daunorubicin-based chemotherapy.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Daunorubicin; Female; Heart Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Razoxane

1998
Antineoplastic activity of continuous exposure to dexrazoxane: potential new role as a novel topoisomerase II inhibitor.
    Seminars in oncology, 1998, Volume: 25, Issue:4 Suppl 10

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Doxorubicin; Heart Diseases; Humans; Razoxane; Topoisomerase II Inhibitors

1998
High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 34, Issue:2

    Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Heart Diseases; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Razoxane; Thrombocytopenia

2001
Dexrazoxane cardioprotection for patients receiving FAC chemotherapy: a pharmacoeconomic evaluation.
    The Canadian journal of oncology, 1996, Volume: 6, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Agents; Cost-Benefit Analysis; Cyclophosphamide; Decision Support Techniques; Doxorubicin; Economics, Pharmaceutical; Female; Fluorouracil; Health Care Costs; Heart; Heart Diseases; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Staging; Razoxane; Sensitivity and Specificity

1996
Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin.
    Journal of the National Cancer Institute, 1992, Nov-18, Volume: 84, Issue:22

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Doxorubicin; Heart Diseases; Humans; Razoxane

1992

Other Studies

34 other study(ies) available for razoxane and Heart Diseases

ArticleYear
Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
    Toxicology, 2013, Sep-15, Volume: 311, Issue:3

    Topics: Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Citrate (si)-Synthase; Daunorubicin; Heart Diseases; Male; NF-E2-Related Factor 2; Oxidative Stress; Rabbits; Razoxane; Troponin T; Ventricular Function, Left

2013
Cardiac lesions induced by testosterone: protective effects of dexrazoxane and trimetazidine.
    Cardiovascular toxicology, 2009, Volume: 9, Issue:2

    Topics: Animals; Cardiotonic Agents; Female; Heart Diseases; Male; Rabbits; Razoxane; Testosterone; Trimetazidine

2009
Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death.
    British journal of cancer, 2009, Sep-01, Volume: 101, Issue:5

    Topics: Animals; Anthracyclines; Apoptosis; Cardiotonic Agents; Cardiotoxins; Heart Diseases; Male; Myocytes, Cardiac; Rabbits; Razoxane

2009
Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Gene Expression; Gene Expression Profiling; Heart Diseases; Male; Mitochondria, Heart; Myocardium; NF-E2-Related Factor 2; Oligonucleotide Array Sequence Analysis; Rats; Rats, Inbred SHR; Razoxane; Reverse Transcriptase Polymerase Chain Reaction; Troponin T

2010
The effect of dexrazoxane for clinical and subclinical cardiotoxicity in children with acute myeloid leukemia.
    Journal of pediatric hematology/oncology, 2010, Volume: 32, Issue:4

    Topics: Adolescent; Anthracyclines; Cardiovascular Agents; Child; Child, Preschool; Female; Follow-Up Studies; Heart Diseases; Humans; Infant; Leukemia, Myeloid, Acute; Male; Prospective Studies; Razoxane; Survival Rate; Treatment Outcome

2010
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.
    Veterinary and comparative oncology, 2010, Volume: 8, Issue:4

    Topics: Animals; Cardiovascular Agents; Dog Diseases; Dogs; Doxorubicin; Drug Therapy, Combination; Gastrointestinal Diseases; Heart Diseases; Neoplasms; Razoxane

2010
Drug may protect children's hearts from chemotherapy.
    ONS connect, 2010, Volume: 25, Issue:12

    Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Doxorubicin; Female; Heart Diseases; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Randomized Controlled Trials as Topic; Razoxane; Sex Characteristics

2010
A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat.
    Toxicologic pathology, 2011, Volume: 39, Issue:7

    Topics: Animals; Apoptosis; Autophagy; Benzamides; Cardiotoxins; Heart Diseases; Imatinib Mesylate; Lysosomal-Associated Membrane Protein 2; Male; Muscle Cells; Myocardium; Oligonucleotide Array Sequence Analysis; Oxidation-Reduction; Piperazines; Pyrimidines; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Razoxane; Sarcomeres; Troponin; Weight Gain

2011
Prevention and treatment of doxorubicin-induced cardiotoxicity by dexrazoxane and schisandrin B in rabbits.
    International journal of toxicology, 2011, Volume: 30, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cardiotonic Agents; Cyclooctanes; Doxorubicin; Female; Heart Diseases; Lignans; Male; Malondialdehyde; Natriuretic Peptide, Brain; Polycyclic Compounds; Rabbits; Razoxane; Superoxide Dismutase; Troponin I

2011
[Echocardiographic assessment of circulation system in patients during and 3-5 years after all therapy in childhood].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 2002, Volume: 55, Issue:3-4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Case-Control Studies; Child; Child, Preschool; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Echocardiography; Female; Heart Diseases; Humans; Infant; Male; Paclitaxel; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Taxoids; Time Factors; Ventricular Function, Left; Ventricular Function, Right

2002
Dexrazoxane does not protect against doxorubicin-induced damage in young rats.
    American journal of physiology. Heart and circulatory physiology, 2003, Volume: 285, Issue:2

    Topics: Age Factors; Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Body Weight; Cell Differentiation; Doxorubicin; Female; Heart Diseases; Heme Oxygenase (Decyclizing); Heme Oxygenase-1; Myocardium; Myocytes, Cardiac; Organ Size; Oxidative Stress; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Sprague-Dawley; Razoxane; Vesicular Transport Proteins

2003
[Cardioxan: prevention of anthracycline-related cardiotoxicity].
    Voprosy onkologii, 2004, Volume: 50, Issue:4

    Topics: Adolescent; Adult; Age Factors; Aged; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cardiotonic Agents; Cardiovascular Agents; Chelating Agents; Child; Clinical Trials as Topic; Doxorubicin; Echocardiography; Electrocardiography; Female; Heart; Heart Diseases; Humans; Immunosuppressive Agents; Leukemia, Experimental; Male; Mice; Mice, Inbred C57BL; Neoplasms; Neoplasms, Experimental; Razoxane; Time Factors

2004
Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:4

    Topics: Animals; Antibiotics, Antineoplastic; Chelating Agents; Daunorubicin; Heart Diseases; Iron Regulatory Protein 1; Iron-Regulatory Proteins; Male; Rats; Rats, Inbred F344; Razoxane

2006
Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane.
    Cancer research, 2007, Sep-15, Volume: 67, Issue:18

    Topics: Animals; Antibiotics, Antineoplastic; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Interactions; Heart Diseases; Histones; Humans; Mice; Models, Molecular; Myocytes, Cardiac; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Conformation; Razoxane; Topoisomerase II Inhibitors

2007
Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells.
    Cancer research, 1993, Feb-01, Volume: 53, Issue:3

    Topics: Adenosine Triphosphate; Animals; Cells, Cultured; Dose-Response Relationship, Drug; Heart Diseases; Humans; Leukemia, Experimental; Male; Mice; Mice, Inbred DBA; Microscopy, Electron; Mitoxantrone; Multiple Myeloma; Myocardium; Rats; Rats, Sprague-Dawley; Razoxane; Sensitivity and Specificity; Tumor Cells, Cultured

1993
Dendritic cells in the hearts of spontaneously hypertensive rats treated with doxorubicin with or without ICRF-187.
    The American journal of pathology, 1993, Volume: 142, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antigen-Presenting Cells; Dendritic Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Heart; Heart Diseases; Immunohistochemistry; Incidence; Macrophages; Male; Myocardium; Rats; Rats, Inbred SHR; Razoxane; Severity of Illness Index; T-Lymphocytes

1993
Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2

    Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane

1996
Anthracycline cardiotoxicity prevention by dexrazoxane: breakthrough of a barrier--sharpens antitumor profile and therapeutic index.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:2

    Topics: Adult; Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Child; Heart; Heart Diseases; Humans; Neoplasms; Razoxane

1996
Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.
    British journal of pharmacology, 1996, Volume: 117, Issue:7

    Topics: Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Daunorubicin; Drug Evaluation, Preclinical; Heart; Heart Diseases; In Vitro Techniques; Liposomes; Male; Myocardium; Rats; Rats, Sprague-Dawley; Razoxane; Ventricular Function, Left; Ventricular Pressure

1996
Preclinical comparison of bis-diketopiperazine-propane (dexrazoxane) and bis-diketopiperazine-ethane (antimet) on the adriamycin-cardiotoxic effect.
    Neoplasma, 1997, Volume: 44, Issue:2

    Topics: Administration, Oral; Animals; Cardiovascular Agents; Doxorubicin; Drug Evaluation, Preclinical; Electroencephalography; Female; Heart Diseases; Myometrium; Piperazines; Rats; Rats, Wistar; Razoxane

1997
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
    Cancer chemotherapy and pharmacology, 2000, Volume: 45, Issue:4

    Topics: Amifostine; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Body Weight; Doxorubicin; Heart Diseases; Hypertension; Kidney; Kidney Diseases; Male; Myocardium; Radiation-Protective Agents; Rats; Rats, Inbred SHR; Razoxane

2000
[Cardiotoxicity of antineoplastic anthracycline antibiotics and prevention by cardioxane (Dexrazoxane) in clinical practice].
    Voprosy onkologii, 2001, Volume: 47, Issue:1

    Topics: Antibiotics, Antineoplastic; Cardiovascular Agents; Heart Conduction System; Heart Diseases; Humans; Razoxane

2001
Modification of doxorubicin-induced cardiotoxicity: effect of essential fatty acids and ICRF-187 (dexrazoxane).
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:11

    Topics: Animals; Antineoplastic Agents; Doxorubicin; gamma-Linolenic Acid; Heart Diseases; Linoleic Acid; Male; Rats; Rats, Sprague-Dawley; Razoxane; Weight Loss

2001
Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters.
    Cancer treatment reports, 1979, Volume: 63, Issue:1

    Topics: Animals; Body Weight; Chemical and Drug Induced Liver Injury; Cricetinae; Daunorubicin; Heart Diseases; Liver; Liver Diseases; Male; Mesocricetus; Myocardium; Piperazines; Rats; Razoxane; Stereoisomerism; Time Factors

1979
Reducing the cardiotoxicity of the anthracyclines.
    Oncology (Williston Park, N.Y.), 1992, Volume: 6, Issue:6

    Topics: Antibiotics, Antineoplastic; Biopsy, Needle; Endocardium; Heart Diseases; Heart Failure; Heart Function Tests; Humans; Myocardium; Neoplasms; Razoxane; Risk Factors; Sensitivity and Specificity

1992
The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:1

    Topics: Animals; Body Weight; Cardiac Output; Dose-Response Relationship, Drug; Doxorubicin; Heart; Heart Diseases; Heart Failure; Heart Rate; Hemorrhage; Male; Pleural Effusion; Rats; Rats, Inbred Strains; Razoxane; Time Factors

1992
Protective effect of ICRF-187 against normal tissue injury induced by adriamycin in combination with whole body hyperthermia.
    Cancer research, 1991, Jul-01, Volume: 51, Issue:13

    Topics: Animals; Blood Cell Count; Body Weight; Combined Modality Therapy; Doxorubicin; Female; Heart Diseases; Hematopoiesis; Hyperthermia, Induced; Kidney Diseases; Nervous System Diseases; Rats; Rats, Inbred F344; Razoxane; Sarcoma, Experimental; Survival Analysis

1991
A drug for prevention of anthracycline-induced cardiac toxicity.
    The Medical letter on drugs and therapeutics, 1991, Sep-06, Volume: 33, Issue:852

    Topics: Adult; Antibiotics, Antineoplastic; Child; Heart Diseases; Humans; Razoxane

1991
Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat.
    Toxicology and applied pharmacology, 1990, Volume: 102, Issue:2

    Topics: Animals; Doxorubicin; Electrocardiography; Female; Heart Diseases; Myocardial Contraction; Myocardium; Myofibrils; Piperazines; Rats; Razoxane; Vacuoles

1990
ICRF 187.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:6

    Topics: Animals; Antineoplastic Agents; Doxorubicin; Heart Diseases; Humans; Piperazines; Razoxane

1989
Protective effect of ICRF-187 on doxorubicin-induced cardiac and renal toxicity in spontaneously hypertensive (SHR) and normotensive (WKY) rats.
    Toxicology and applied pharmacology, 1988, Volume: 92, Issue:1

    Topics: Animals; Blood Pressure; Body Weight; Doxorubicin; Drug Interactions; Heart Diseases; Heart Rate; Kidney Diseases; Male; Piperazines; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Razoxane; Species Specificity

1988
Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds.
    Cancer treatment reviews, 1987, Volume: 14, Issue:3-4

    Topics: Acetylcysteine; Animals; Dogs; Doxorubicin; Heart Diseases; Piperazines; Razoxane; Swine; Vitamin E

1987
Pretreatment with ICRF-187 allows a marked increase in the total cumulative dose of doxorubicin tolerated by beagle dogs.
    Drugs under experimental and clinical research, 1988, Volume: 14, Issue:9

    Topics: Animals; Dogs; Doxorubicin; Drug Interactions; Drug Tolerance; Echocardiography; Electrocardiography; Heart; Heart Diseases; Liver; Myocardium; Piperazines; Razoxane

1988
Reduction of chronic doxorubicin cardiotoxicity in beagle dogs by bis-morpholinomethyl derivative of razoxane (ICRF-159).
    Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:4

    Topics: Animals; Blood Cell Count; Body Weight; Dogs; Doxorubicin; Drug Evaluation, Preclinical; Female; Heart Diseases; Hematocrit; Hematologic Diseases; Male; Piperazines; Razoxane

1987